Local the rapy ofmiddle and inn er ear di sea ses is bein g used, but is restricted to cases ofear drum perforation or to rep eated invasiv e intratytnpanic dru g application by the ph ysician .
Introduction
Local therapy of middle and inner car diseases is restricted to cases of car drum perforation or to invasive intratympanic drug application by the physician. Typical examples are gentamycin therapy for Meniere' s disease and cortisone application for secretory otitis media. We present the first developmental steps of an implantable drug delivery system designed to replace invasive drug application by the physician.
Conventional implantable drug delivery systems are designed for implantation in the abdominal region. They have large housing volumes, weights above 250 g. and are driven by battery ortwe-phase gas pressure. Usually, they work with fixed or programmable basal rates and do not provide patient-controlled bolus application (bolus on demand). Conventional implants are used primarily in therapy for pain, cancer and spasticity.
Bycontrast, our aim is to design a specific drug delivery system for local bolus therapy of the middle and inner ear; a totally implantable drug delivery system (TI-DDS). Maximum size and required implantation technique are expected to be similar to those of cochlear implant receivers.To reduce costs and housing volumes, a power source, such as batteries, is not used.
Materials and Methods
The 2D and 3D layouts were accomplished with computer-aided design (AutoCAD ReI. 12.0). The supplier of pure titanium (grades 2 and 5) was Tisto (Duesseldorf, Germany). The implantable-grade ultra-high molecular 
Results and Discussion
In accordance with the Medical Device Directive (Class III). a bone-anchored. totally implantable drug delivery system was developed. It includes three modules: a micropump for percutaneous. patient-controlled Figure 1 . The modular pump unit. activation. a flexible drug reservoir with a 5 to 8 ml volume capacity and a septum port designed to refill the system with a Huber canulla (27 gauge ). The actual des ign is modular. The design of the pump module is shown in Figure I . which shows a piston pump in a round flat hou sing not more than 6.5 mm high. The valves are activated by the fluid pressure in the pump chamber. When the piston is pressed down. the fluid pressure in the pump chamber increases above 200 mbar and open s the outlet valve. A drug bolu s of 25~I can now flow through the thin guidewire catheter to the site ofapplication in the mastoid or middle ear cavi ties. After Figure 2 . The modular port unit. releasing the finger pressure. the piston will be returned by the spring to its starting position . The increasing vacuum allows new fluid to flow through the inlet valve into the pump chamber.
The digital pressure force required to drive the pump is 5 to 8 Newtons. and the piston displacement is I mm.Implantable biomaterials were used for all parts of the pump module. The dome-shaped membrane and the two-valve membranes are made of sil icone. and the piston of UHMW pol yethylene (Hostalen). Pure titanium was used for the spring material and all hou sing part s. The modular port. shown in Figu re 2. is 6 mm high. A titanium hou sin g includ es a selfsealing septum and a"ring -shaped particle filter with 5 urn poro sity. A Huber canulla (27 gauge) is used to refill the sys tem. The hou sing and filter are mad e of pure titanium. and the septum material is silicone. As an elastic reservoir we use a flat silicone tissue expander with 5 to 8 ml of storage volume ( Figure 3 ). stored drug volume provides 250 patient-controlled bolus applications with one filling.
Summary
Local drug treatment of lidocaine-sensitive tinnitus, secretory otitis media, Meniere's disease or pain therapy with the TI-DDS is under discussion. Furthermore, inner ear therapy applying biotechnological trophic factors through the round window membrane is anticipated.
The TI-DDS has undergone extensive in vitro testings, with promising results of pump rate precision and digital pressure force testing. The designed pump unit is able to work with liquids and gases. Tests show that gas bubbles or particles carried by the fluid do not interfere with the TI-DDS' function. Long-term in vitro tests on the interaction between selected biomaterials and drugs are under way, and initial animal tests are in preparation. Thus, the TI-DDS provides the opportunity for a wide range oflocal drug therapy in the middle and inner ear. In the future, it may be possible to provide a subpopulation of otology patients with the new bone-anchored, totally implantable system for subcutaneous implantation similar to the cochlear implant receiver. The main advantages of the TI-DDS are:
• Patient-controlled bolus application, specifically into the mastoid cavity or middle ear, or onto the round window membrane; • Dose reduction due to local application; • Reduced side effects (compared to systemic therapy); • No battery required; and • Low product costs. Research and Technology (BMBF. No.: 01 VJ 9313) .
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predictive at human response. General consideration should be given to thislactbelore administering lidocaine to women ofchildbearing potential, especially during earty pregnancy wh.. maximum organogenesIs lakes place.
loIIor II1II Doll.",: Lidocaine is notcontraindicated Inlabor and delivery. Should Xylocaine 10% Oral Spray be used concomitantly with other products containing lidocaine, the total dose contributed byaillormulalions must be kept In mind. N••"" Molho,,: It is notknown whether thisdrug Is excreted In human milk. Because many drugs are excreted in human milk, caution should be exercised when lidocaine isadministered toanursing woman. Poclotsk U..: safety and effectiveness Inchildren below theage 0112 years have notbeen established.
OVIRSI RlAcnONS
Adverse experiences following theadministration of lidocaine are similar Innature 10 those observed with other amide local aneslhetic agents. These adverse experiences are, ingeneral, dose-related and may resub Irom high plasma levels caused byexcessive dosage or rapid absorption, or may resun from a hypersensitivity, idiosyncrasy or diminished tolerance onthe part 01 the patient. Serious adverse experiences are generally systemic Innature. The lollowing types are those most commonly reported: (••,,,1 NerYltl S,.I••: CNS manifestations areexcitatory and/or depressant and may becharacterized by Iightheadedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or double vision, vomiting, sensations of heat, cold ornumbness, twitching, tremors, convulsions, unconsciousness, respiratory depression and arrest. The excitatory manifestations may bevery brief or may noloccur atall, Inwhich case the IIrst manllestatlon 01 toxitlty may bedrowsiness merging Inlounconsciousness and respiratory arresl. Drowsiness loliowlng the admlnistralion of lidocaine is usually anearly sign ofa high blood level 01 the drug and may occur asaconsequence ofrapid absorpllon. The tlrststep inthe management atconvulsions consists ofImmediate adentlon tothemaintenance ofapatent airway and assisted or controlled ventilation withoxygen and a delivery system capable of permidlng Immediate positive airway pressure by mask. Immediately after theinstllution of these ventllalory measures, theadequacy of the circulation should beevalualed, keeping in mind Ihaldrugs used 10 treat convulsions sometimes depress the circulation when administered Intravenously. Should convulsions persist despite adequate respiratory support, and if thestatus of thecirculation permits, small Increments of an ultra-short acting barbiturate (such asIhiopental or thiamylal) ora benzodlazepine (such asdiazepam) may beadministered intravenously. The clinician should befamiliar, priorto use of local aneslhetics, wbh these anticonvulsant drugs. SUpportive treatment of Circulatory depression may require administration ofIntravenous fluids and, when appropriate, a vasopressor asdirected bytheclinical situation (e.g., ephedrine). 
